Finally, although recent studies suggest that certain antidiabetic medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, may exert neuroprotective effects in PD, our dataset did not include pharmacological treatment information. This evidence concerns the gene SLC5A2 and Parkinson disease.